Krka Halts Sale of Zalasta in Germany
Novo mesto, 19 December - Slovenian drug company Krka has stopped marketing Zalasta, a drug for the treatment of schizophrenia, in Germany via its subsidiary TAD Pharma after the German Supreme Court ruled that the patent protecting Olanzapine, the active substance in this drug, remains valid.
The rest of this news item is available to subscribers.
The news item consists of 198 characters (without spaces) or 43 words words.
Buy the news item. Price: 2 tokens; on account: 0 tokens.